6/106 sources · 4 publishersUpdated Nov 6, 23:20 UTC
bioAffinity Technologies posts Q3 2026 revenue decline and wider net loss
+1 new source since this summary was written
bioAffinity Technologies reported third‑quarter 2026 revenue of $1.07 million, down 26% year‑over‑year, and a net loss of $5.28 million, or $5.89 per share. Cash and cash equivalents fell to $2.55 million at quarter‑end, and the company raised about $4.0 million in a subsequent financing. The decline was driven by lower CyPath Lung testing revenue despite higher test volumes.
Why it matters
The widened loss and reduced cash balance signal tighter liquidity, prompting the need for additional financing, which may affect short‑term financing costs and dilution for shareholders ().
Key facts
- 1Q3 2026 revenue was $1.07 million, compared with $1.45 million in the year‑earlier quarter. tradingview.com
- 2Net loss for the quarter was $5.28 million, or $5.89 per basic and diluted share. tradingview.com
- 3Cash and cash equivalents totaled $2.55 million at September 30, 2026. tradingview.com
- 4The company generated approximately $4.0 million in gross proceeds from a subsequent financing. tradingview.com
- 5CyPath Lung test unit sales increased 100% year‑over‑year through the first nine months of 2026. tradingview.com
- 6The company had 11 active clinical trial sites at quarter‑end. tradingview.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.